Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1/CTLA-4 bispecific): a case report and literature review

Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1/CTLA-4 bispecific): a case report and literature review

Objectives: For advanced ovarian cancer (OC), particularly OC with HR-deficient, surgery combined with adjuvant chemotherapy and maintenance therapy with PARPi/bevacizumab is the standard effective first-line treatment regimen. However, the clinical benefit of therapy for HR-proficient advanced OC i...

Full description

Saved in:
Bibliographic Details
Main Authors: Chenge Zhang, Miao Dai, Jun Yang, Wenfang Tian, Si Huang, Feng Bi, Kai Zheng, Jie Tang
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Gynecologic Oncology Reports
Subjects:
Advanced ovarian cancer
AK104/Cadonilimab
PD-1/CTLA-4 bispecific antibody
Complete response
HR-proficient
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578925001109
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items